This means the enriched pathways, such as the MAPK and PI3K-Akt signaling cascades, reflect baricitinib’s potential engagement with biological processes central to, but not exclusive to, CKD pathogenesis. This evidence concerns the gene AKT1 and chronic kidney disease.